Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
December 6, 2023 04:47 PM ESTUpdated 05:51 PM
Deals
Pharma

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el 

Kyle LaHucik

Senior Reporter

Ab­b­Vie said Wednes­day evening it plans to pay $8.7 bil­lion to ac­quire neu­ro­science drug­mak­er Cerev­el Ther­a­peu­tics in a deal that comes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times